BG103723A - Пиразинови съединения - Google Patents

Пиразинови съединения Download PDF

Info

Publication number
BG103723A
BG103723A BG103723A BG10372399A BG103723A BG 103723 A BG103723 A BG 103723A BG 103723 A BG103723 A BG 103723A BG 10372399 A BG10372399 A BG 10372399A BG 103723 A BG103723 A BG 103723A
Authority
BG
Bulgaria
Prior art keywords
compound
formula
pyrazine
alkyl
trichlorophenyl
Prior art date
Application number
BG103723A
Other languages
Bulgarian (bg)
English (en)
Inventor
Brian Cox
Dean EDNEY
Michael LOFT
Malcolm NOBBS
Gita Shah
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9704275.8A external-priority patent/GB9704275D0/en
Priority claimed from GBGB9708183.0A external-priority patent/GB9708183D0/en
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of BG103723A publication Critical patent/BG103723A/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Detergent Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
BG103723A 1997-03-01 1999-09-09 Пиразинови съединения BG103723A (bg)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9704275.8A GB9704275D0 (en) 1997-03-01 1997-03-01 Pharmacologically active compound
GBGB9708183.0A GB9708183D0 (en) 1997-04-23 1997-04-23 Pharmacologically active compound
PCT/EP1998/001077 WO1998038174A1 (en) 1997-03-01 1998-02-26 Pyrazine compounds

Publications (1)

Publication Number Publication Date
BG103723A true BG103723A (bg) 2001-05-31

Family

ID=26311097

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103723A BG103723A (bg) 1997-03-01 1999-09-09 Пиразинови съединения

Country Status (46)

Country Link
US (2) US6255307B1 (cs)
EP (1) EP0966448B1 (cs)
JP (1) JP3369189B2 (cs)
KR (1) KR100544263B1 (cs)
CN (1) CN1105111C (cs)
AP (1) AP9901632A0 (cs)
AR (1) AR011174A1 (cs)
AT (1) ATE251143T1 (cs)
AU (1) AU732915B2 (cs)
BG (1) BG103723A (cs)
BR (1) BR9807814B1 (cs)
CA (1) CA2282585C (cs)
CO (1) CO4950513A1 (cs)
CZ (1) CZ295618B6 (cs)
DE (1) DE69818643T2 (cs)
DK (1) DK0966448T3 (cs)
EA (1) EA002102B1 (cs)
EE (1) EE9900376A (cs)
ES (1) ES2205469T3 (cs)
GE (1) GEP20012555B (cs)
GT (1) GT199800046A (cs)
HK (1) HK1023116A1 (cs)
HN (2) HN1998000036A (cs)
HR (1) HRP980107A2 (cs)
HU (1) HU225852B1 (cs)
ID (1) ID22850A (cs)
IL (1) IL131293A (cs)
IS (1) IS5163A (cs)
JO (1) JO2035B1 (cs)
MA (1) MA26473A1 (cs)
MY (1) MY118612A (cs)
NO (1) NO313383B1 (cs)
NZ (1) NZ337121A (cs)
OA (1) OA11151A (cs)
PA (1) PA8448201A1 (cs)
PE (1) PE58299A1 (cs)
PL (1) PL192864B1 (cs)
PT (1) PT966448E (cs)
SI (1) SI0966448T1 (cs)
SK (1) SK117399A3 (cs)
SV (1) SV1998000029A (cs)
TR (1) TR199902082T2 (cs)
TW (1) TW513416B (cs)
UY (1) UY24911A1 (cs)
WO (1) WO1998038174A1 (cs)
YU (1) YU40799A (cs)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6420354B1 (en) 1998-06-08 2002-07-16 Advanced Medicine, Inc. Sodium channel drugs and uses
GB9818881D0 (en) 1998-08-28 1998-10-21 Glaxo Group Ltd Compounds
GB9907965D0 (en) * 1999-04-09 1999-06-02 Glaxo Group Ltd Medical use
US6479498B1 (en) 1999-06-04 2002-11-12 Theravance, Inc. Sodium channel drugs and uses
EP1500653A1 (en) * 2000-02-16 2005-01-26 Neurogen Corporation Substituted arylpyrazines
US6995161B2 (en) * 2000-02-16 2006-02-07 Neurogen Corporation Substituted arylpyrazines
GB0010971D0 (en) * 2000-05-05 2000-06-28 Glaxo Group Ltd Process
GB0016040D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
SE0102439D0 (sv) * 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
SE0102438D0 (sv) * 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
CA2467870A1 (en) * 2001-11-21 2003-06-05 Pharmacia & Upjohn Company Substituted aryl 1,4-pyrazine derivatives
US6992087B2 (en) 2001-11-21 2006-01-31 Pfizer Inc Substituted aryl 1,4-pyrazine derivatives
SI1458386T1 (sl) 2001-12-27 2007-08-31 Ortho Mcneil Pharm Inc Aroil pirol heteroeril in metanoli, uporabni za zdravljenje motnje centralnega živčnega sistema
CA2480497A1 (en) 2002-04-26 2003-11-06 Pharmacia & Upjohn Company Substituted pyrazine derivatives
US7179807B2 (en) 2002-08-20 2007-02-20 Neurogen Corporation 5-substituted-2-arylpyrazines
SE0203753D0 (sv) * 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
SE0203754D0 (sv) * 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
CA2514574A1 (en) 2003-01-30 2004-08-12 Dynogen Pharmaceuticals, Inc. Use of sodium channel modulators for treating gastrointestinal tract disorders
TW200510373A (en) * 2003-07-14 2005-03-16 Neurogen Corp Substituted quinolin-4-ylamine analogues
BRPI0607308A2 (pt) 2005-01-25 2009-08-25 Synta Pharmaceuticals Corp compostos, composições farmacêuticas e usos dos referidos compostos
EP1853230A2 (en) * 2005-02-15 2007-11-14 Jazz Pharmaceuticals Inc. Dosage form and method for sustained release of a substituted pyrazine compound
NL2000284C2 (nl) * 2005-11-04 2007-09-28 Pfizer Ltd Pyrazine-derivaten.
US20100240652A1 (en) * 2006-01-23 2010-09-23 Pfizer Inc Pyridine Derivatives as Sodium Channel Modulators
JP2010526051A (ja) * 2007-05-03 2010-07-29 ファイザー・リミテッド 疼痛を治療するためのｎａｖ１．８チャネルモジュレーターとしてのｎ−［６−アミノ−５−（フェニル）ピラジン−２−イル］−イソオキサゾール−４−カルボキサミド誘導体および関連化合物
GB0800741D0 (en) 2008-01-16 2008-02-20 Univ Greenwich Cyclic triazo and diazo sodium channel blockers
GB201111712D0 (en) 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
FR3001151B1 (fr) 2013-01-21 2016-04-08 Pf Medicament Association d'un bloqueur de courant sodique lent et d'un inhibiteur du courant if sinusal et les compositions pharmarceutiques la contenant
JO3517B1 (ar) * 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
CN109415360B (zh) 2016-06-14 2021-11-02 诺华股份有限公司 用于抑制shp2活性的化合物和组合物
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
CN108101857B (zh) * 2016-11-24 2021-09-03 韶远科技（上海)有限公司 制取2-氨基-3-溴-6-氯吡嗪的可放大工艺
CN107011273A (zh) * 2017-05-04 2017-08-04 无锡捷化医药科技有限公司 一种合成6‑碘‑3‑(2,3‑二氯苯基)吡嗪‑2‑胺的方法
CN113473980A (zh) 2019-03-01 2021-10-01 弗拉梅尔爱尔兰有限公司 在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
CN115611700A (zh) * 2022-10-11 2023-01-17 辽宁东大光明化工科技有限责任公司 一种1-溴-2,5-二氯-3-氟苯的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4402958A (en) 1981-11-19 1983-09-06 American Cyanamid Company Novel (substituted phenyl)-1,2,4-triazolo (4,3-A)pyrazines and novel 2-hydrazino-(substituted phenyl)pyrazine intermediates
DE3873812D1 (de) 1987-04-07 1992-09-24 Ciba Geigy Ag 3h-1,2,3-triazolo(4,5-d)pyrimidine.
JPH08238778A (ja) * 1995-03-07 1996-09-17 Brother Ind Ltd インク噴射装置の電極形成方法

Also Published As

Publication number Publication date
JP3369189B2 (ja) 2003-01-20
PA8448201A1 (es) 2000-05-24
DK0966448T3 (da) 2004-02-02
HUP0001802A2 (hu) 2001-05-28
SI0966448T1 (en) 2004-04-30
OA11151A (en) 2003-04-22
BR9807814B1 (pt) 2009-01-13
MY118612A (en) 2004-12-31
NO994213L (no) 1999-10-29
ID22850A (id) 1999-12-09
HRP980107A2 (en) 1998-12-31
JO2035B1 (en) 1999-05-15
GT199800046A (es) 1999-08-20
GEP20012555B (en) 2001-10-25
CZ311199A3 (cs) 2000-02-16
PL335441A1 (en) 2000-04-25
YU40799A (sh) 2001-09-28
DE69818643D1 (de) 2003-11-06
SK117399A3 (en) 2000-06-12
CN1105111C (zh) 2003-04-09
US6255307B1 (en) 2001-07-03
AR011174A1 (es) 2000-08-02
NO994213D0 (no) 1999-08-31
ATE251143T1 (de) 2003-10-15
HU225852B1 (en) 2007-11-28
HN1998000036A (es) 1999-08-23
ES2205469T3 (es) 2004-05-01
CZ295618B6 (cs) 2005-09-14
IS5163A (is) 1999-08-24
HK1023116A1 (en) 2000-09-01
US6599905B2 (en) 2003-07-29
EP0966448B1 (en) 2003-10-01
UY24911A1 (es) 2000-12-29
PE58299A1 (es) 1999-06-23
US20020169172A1 (en) 2002-11-14
CA2282585C (en) 2006-06-06
AP9901632A0 (en) 1999-09-30
MA26473A1 (fr) 2004-12-20
IL131293A0 (en) 2001-01-28
HUP0001802A3 (en) 2001-07-30
JP2000511203A (ja) 2000-08-29
WO1998038174A1 (en) 1998-09-03
PL192864B1 (pl) 2006-12-29
IL131293A (en) 2003-07-31
CN1253551A (zh) 2000-05-17
EP0966448A1 (en) 1999-12-29
DE69818643T2 (de) 2004-10-07
HN1999000019A (es) 1999-08-23
CA2282585A1 (en) 1998-09-03
EE9900376A (et) 2000-04-17
TR199902082T2 (xx) 2000-04-21
CO4950513A1 (es) 2000-09-01
NO313383B1 (no) 2002-09-23
AU6823798A (en) 1998-09-18
TW513416B (en) 2002-12-11
BR9807814A (pt) 2000-02-22
PT966448E (pt) 2004-02-27
KR20000075859A (ko) 2000-12-26
EA199900687A1 (ru) 2000-04-24
AU732915B2 (en) 2001-05-03
NZ337121A (en) 2001-03-30
KR100544263B1 (ko) 2006-01-23
EA002102B1 (ru) 2001-12-24
SV1998000029A (es) 1998-12-11

Similar Documents

Publication Publication Date Title
BG103723A (bg) Пиразинови съединения
CN115135650A (zh) 作为kras抑制剂的吡啶并嘧啶衍生物
CN102329325B (zh) 吡咯并嘧啶酮类dpp-iv抑制剂
MX2014013166A (es) Derivados de 2-amino-4-(bencilamino)fenilcarbamato fluorados.
US6503909B1 (en) Pyrazine compounds
CA2853008A1 (en) Pharmaceutical compounds
CN107438604B (zh) 新吡啶化合物
HU229929B1 (en) Substituted homopiperidinyl benzimidazole analogues as fundic relaxants, process for their preparation and pharmaceutical compositions containing them
CN101209994B (zh) 选择性m4受体拮抗剂及其医药用途
TW201925179A (zh) 治療疼痛及疼痛相關病症之新型烷氧基胺基衍生物
EP0111151B1 (en) Substituted nitropyrazine compounds, process for their preparation and pharmaceutical compositions containing them
WO2017215586A1 (zh) 酰胺类衍生物、其制备方法及其在医药上的用途
MXPA99007910A (en) Pyrazine compounds
MXPA01001983A (en) Pyrazine compounds
JP2002308773A (ja) ピラジン化合物
KR20050019935A (ko) 피라진 화합물을 포함하는 제약 조성물
JPH10204087A (ja) 縮合ピリダジン誘導体、その製造法および剤